The Federal Minister for National Health Services, Regulations and Coordination Syed Mustafa Kamal welcomed the announcement by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) on the designation of the Drug Regulatory Authority of Pakistan (DRAP) as an Observer at the ICH Assembly held on 2-3 June 2026 in Rio de Janeiro, Brazil.
Congratulating the nation on this landmark achievement, the minister termed it a major step forward in Pakistan’s journey towards a modern, globally integrated regulatory system, said a press release on Friday.
As a globally recognized platform, ICH brings together leading regulatory authorities and industry to develop harmonised technical guidelines that ensure the quality, safety, and efficacy of medicines. Engagement at this level will enable Pakistan to benefit from global best practices, while contributing to ongoing international regulatory dialogue.
This development is expected to strengthen regulatory capacity, improve transparency and efficiency, and enhance confidence in the national pharmaceutical system. It will also open new avenues for the domestic industry to align with international standards and expand its global footprint.
This milestone reflects the Government’s steadfast commitment to advancing the vision of the Honourable Prime Minister of Pakistan for modernizing public institutions, strengthening the health system, and ensuring Pakistan’s alignment with internationally recognised best regulatory practices.
“Alhamdolillah, DRAP’s recognition as an ICH Observer is a landmark achievement that reflects Pakistan’s determined progress towards global regulatory alignment.